Megan Kruse, MD

Drs Nunnery and Kruse discuss the controversy surrounding a biomarker-driven switch strategy in hormone receptor–positive, HER2-negative breast cancer.

Megan Kruse, MD, discusses the evolving role of FES-PET/CT in breast cancer, particularly invasive lobular carcinoma.

Dr. Kruse reviews ASCENT-03 and TROPION-Breast02 data for PD-L1-negative or checkpoint inhibitor-ineligible metastatic TNBC, noting unsurprising ADC superiority in first-line treatment.

Dr. Kang describes ASCENT-04 results as logical and practice-changing for PD-L1-positive metastatic TNBC.

Dr. Kruse discusses Dato-DXd placement in hormone receptor-positive, HER2-negative metastatic disease following TROPION-Breast01 results.

Dr. Kruse addresses the complexity introduced by simultaneous release of DESTINY-Breast05 and -11 data, requiring contextualization of both neoadjuvant and adjuvant approaches.

Dr. Kruse describes DESTINY-Breast12 as providing crucial reassuring data regarding T-DXd activity in patients with brain metastases.

Dr. Kruse discusses DESTINY-Breast09 as a transformative study challenging the long-standing CLEOPATRA regimen (docetaxel, trastuzumab, pertuzumab) for first-line HER2-positive metastatic breast cancer.

Dr. Kruse addresses patient selection for TROP2-targeted ADC therapy, noting that TROP2 expression intensity does not correlate with therapeutic efficacy. The current therapeutic landscape includes datopotamab deruxtecan (Dato-DXd) and SG, each with distinct toxicity profiles. Selection decisions involve multifactorial considerations including disease progression patterns, prior progression-free survival (PFS) duration, disease location (visceral versus bone-only), and individual patient preferences regarding treatment scheduling and toxicity management.

Dr. Irene Kang from City of Hope Orange County and Dr. Megan Kruse from Cleveland Clinic introduce this OncLive Insights program reviewing HER2 and TROP2-directed antibody drug conjugates (ADCs) in breast cancer. Dr. Kruse emphasizes that 2025 and 2026 represent a transformative period for ADCs, with expanding utility across all breast cancer subtypes and treatment settings. Previously confined to later-line therapy or HER2-positive disease, ADCs now have indications spanning hormone receptor-positive, HER2-positive, and triple-negative breast cancer (TNBC) across first-line, second-line, and later-line settings, with increasing penetration into early-stage disease.

Megan Kruse, MD, emphasizes the importance of observing Triple-Negative Breast Cancer Day through continued disease education and treatment development.

Drs Kruse and O’Brien highlight the various roles of imaging modalities in breast cancer diagnosis and treatment decision-making.

Experts share vital insights on managing HR-positive breast cancer, emphasizing education, patient quality of life, and the evolving landscape of therapies.

Engaging Long-Term HR Positive Metastatic Patients in Shared Decision Making

Clinicians explore essential pre-treatment assessments and monitoring strategies to manage toxicities from new cancer therapies effectively.

Early intervention in cancer treatment aims to enhance patient quality of life and longevity, balancing therapy effectiveness with individual needs.

Experts discuss the evolving landscape of breast cancer treatment, emphasizing the importance of ctDNA testing for personalized therapy decisions.

Experts discuss balancing efficacy and quality of life in SERD therapies, highlighting unique toxicities and the importance of patient education.

Early detection of ESR1 mutations in breast cancer enhances treatment strategies, potentially improving patient outcomes and quality of life.

Clinicians explore the differences between EMERALD and EMBER3 trials, focusing on patient characteristics, treatment efficacy, and future therapy roles.

Oral SERDs emerge as a standard treatment for HR-positive, HER2-negative metastatic breast cancer, especially for patients with ESR1 mutations.

Oral SERDs emerge as a standard treatment for HR-positive, HER2-negative metastatic breast cancer, especially for patients with ESR1 mutations.

Experts discuss the impact of biomarkers and treatment duration on decision-making for CDK4/6 inhibitors in breast cancer adjuvant therapy.

Discover effective strategies for managing toxicities in patients using CDK4/6 inhibitors, ensuring adherence and optimal treatment outcomes.

Clinicians explore barriers to adjuvant CDK4/6-inhibitor therapy, emphasizing education and streamlined communication to improve patient outcomes.

Experts discuss advancements in HR-positive breast cancer treatment, focusing on CDK4/6 inhibitors, SERDs, and early intervention strategies.

Experts discuss advancements in HR-positive breast cancer treatment, focusing on CDK4/6 inhibitors, SERDs, and early intervention strategies.

CDK4/6 Inhibition in HR-Positive Breast Cancer: Evolving Standards in Early and Metastatic Care

Megan Kruse, MD, discusses long-term outcomes adjuvant abemaciclib with endocrine therapy in HR-positive, HER2-negative, high-risk early breast cancer.